Skip to main content
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc — Investor Relations & Filings

Ticker · PRLD ISIN · US74065P1012 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2023-12-13 Director's Dealing
Country US United States of America
Listing US PRLD

About Prelude Therapeutics Inc

https://preludetx.com/

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing innovative medicines for cancer patients with high unmet needs. The company's pipeline features small molecule therapies and leverages expertise in targeted protein degradation. Key development programs include highly selective KAT6A degraders for solid tumors, such as ER+ breast cancer, and mutant-selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms. Prelude is also advancing next-generation degrader antibody conjugates (DACs) with novel payloads. The company's science-driven approach targets critical cancer cell pathways to create potentially transformative treatments.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-12-13 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or corporate changes. The content focuses on the entry into a material definitive agreement related to a securities purchase agreement and unregistered sales of equity securities. It details a private placement offering of pre-funded warrants and related registration rights agreements. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, governance, or management report. It is primarily an announcement of a capital raising transaction and related agreements. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is substantial (over 10,000 characters), indicating it is the report itself, not just an announcement of a report publication. Confidence is high given the clear description of financing activities and the SEC Form 8-K context.
2023-12-11 English
SCHEDULE 13G
Major Shareholding Notification
2023-11-13 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-01 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 1, 2023, reporting the company's financial results for the quarter ended September 30, 2023. It specifically states that the company issued a press release announcing these financial results, and the press release is attached as an exhibit. The document itself is a current report notifying the market of the earnings release, not the earnings release document itself. The length is 3641 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Earnings Release (ER) announcement.
2023-11-01 English
PRIMARY DOCUMENT
Director's Dealing
2023-10-06 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.